Man­u­fac­tur­ing roundup: Gen­Sight ter­mi­nates batch of gene ther­a­py; Evonik opens lipid pro­duc­tion site in Ger­many

Gen­Sight Bi­o­log­ics’ gene ther­a­py treat­ment for Leber hered­i­tary op­tic neu­ropa­thy, called Lumevoq, had an op­er­a­tional is­sue oc­cur dur­ing the man­u­fac­tur­ing process for one of its batch­es.

In a re­lease, the gene ther­a­py biotech stat­ed that the op­er­a­tional is­sue oc­curred in the down­stream process lead­ing to the ter­mi­na­tion of the batch. The root cause is now be­ing in­ves­ti­gat­ed in col­lab­o­ra­tion with Ther­mo Fish­er Sci­en­tif­ic, as its sub­sidiary, Bram­mer Bio, is its man­u­fac­tur­ing part­ner in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER